From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding
Frontiers in Cardiovascular Medicine · 25.06.2026 · 13
DOI: 10.3389/fcvm.2026.1846208 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 25.06.2026. Verfasst von Wei Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Second Affiliated Hospital of Army Medical University, Chongqing, China. Die Arbeit nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background Anticoagulant therapy is indispensable for thromboembolism management, yet it presents an inherent pharmacological paradox by elevating the risk of catastrophic hemorrhage. Navigating this dynamic hemostatic equilibrium remains a profound clinical challenge. Pharmacological landscape This review systematically evaluates the evolution of procoagulant strategies. While specific reversal agents (e.g., idarucizumab, andexanet alfa) have inaugurated an era of targeted precision reversal through high-affinity molecular neutralization, their widespread application is frequently hampered by exorbitant pharmacoeconomic costs, limited accessibility, and latent prothrombotic “off-target” effects (e.g., TFPI inhibition). Conversely, non-specific agents, epitomized by four-factor prothrombin complex concentrate (4F-PCC) and adjunctive antifibrinolytics, retain a foundational, highly cost-effective role in real-world rescue paradigms. Technological innovations To circumvent existing limitations, current technological trajectories are pivoting towards the rational design of broad-spectrum synthetic molecules (e.g., ciraparantag) and highly programmable nucleic acid aptamer systems. These innovations promise to deliver “on-demand” reversibility and democratize access to hemostatic therapies. Clinical management & perspectives Translating these pharmacological breakthroughs into optimal patient outcomes necessitates a paradigm shift in clinical workflows. We propose a multidimensional framework driven by point-of-care (POC) viscoelastic testing, algorithmic clinical decision support systems, and sequential therapy pathways managed by multidisciplinary “Code Bleed” teams. Future research must urgently prioritize large-scale, head-to-head randomized trials focused on patient-centered hard endpoints, ultimately refining evidence-based strategies to maximize therapeutic efficacy while strictly mitigating thrombotic risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Second Affiliated Hospital of Army Medical University, Chongqing, China.
- Department of Special War Wound, Daping Hospital, Army Medical University, Chongqing, China.
Zitieren
APA
Zheng, W., Wang, Y., Lu, J., Long, M., Tang, C., Xu, Z., & Li, H. (2026). From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1846208
Vancouver
Zheng W, Wang Y, Lu J, Long M, Tang C, Xu Z, et al. From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1846208
BibTeX
@article{Zheng2026,
author = {Zheng, Wei and Wang, Yunqiao and Lu, Jing and Long, Mengyang and Tang, Cuiyao and Xu, Zihui and Li, Han},
title = {From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1846208}
}
EUVIMED